A Swedish population registry-based cohort study found a borderline significant increased risk of invasive cancer in patients treated with fingolimod compared to the general population (HR 1.53, 95% CI 0.98–2.38) ( 87 ).
← all excerpts
Risk of cervical pre-cancer and cancer in women with multiple sclerosis exposed to high efficacy disease modifying therapies.
1
—
—